Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with ...
DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...
Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth license option under a 2013 collaboration with Oxford BioTherapeutics.
Boehringer Ingelheim, the makers of FRONTLINE ®, have introduced FRONTPRO as an innovative expansion of the FRONTLINE product family. FRONTPRO is currently available through e-retailers including Pet ...
Boehringer Ingelheim has taken an option on a family ... that spans both pharmacological and digital therapeutic (DTx) products. Leading the charge for new drug therapies is iclepertin (also ...
Orphan Drugs Market Orphan Drugs Market Dublin, Jan. 22, 2025 (GLOBE NEWSWIRE) -- The "Orphan Drugs - Global Strategic ...
Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...
VANCOUVER, BRITISH COLUMBIA, CANADA, January 19, 2025 /EINPresswire / -- The Bovine Tuberculosis (TB) Diagnosis market is expected to grow from USD 781.5 million in 2024 to USD 1.16 billion by 2033, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback